| ADAS-Cog (12-month follow-up) | E-ADL test (12-month follow-up) | ||||
---|---|---|---|---|---|---|
Independent variablea | Unstandardized β (95% CI) | t | P value | Unstandardized β (95% CI) | t | P value |
Scoreb at baseline | 0.82 (0.59-1.05) | 7.14 | < 0.001 | 0.80 (0.54-1.06) | 6.23 | < 0.001 |
Group (control = 0 vs. MAKS = 1) | -7.67 (-13.97--1.37) | -2.44 | 0.018 | 3.57 (0.72-6.42) | 2.52 | 0.015 |
Age | 0.13 (-0.47-0.73) | 0.43 | 0.67 | 0.08 (-0.19-0.35) | 0.58 | 0.57 |
Gender | 1.02 (-6.90-8.94) | 0.26 | 0.80 | 0.91 (-2.64-4.46) | 0.51 | 0.61 |
Medication scorec | -0.38 (-2.14-1.39) | -0.43 | 0.67 | -0.02 (-0.81-0.77) | -0.05 | 0.96 |
NOSGER, moodd | 0.80 (-0.23-1.82) | 1.56 | 0.13 | -0.14 (-0.59-0.31) | -0.63 | 0.53 |
Participation scoree | -0.07 (-0.14--0.01) | -2.22 | 0.03 | 0.01 (-0.02-0.04) | 0.82 | 0.42 |
Use of anti-dementia medicationf | -5.96 (-16.42-4.51) | -1.14 | 0.26 | 0.76 (-3.91-5.43) | 0.33 | 0.74 |